INO — Inovio Pharmaceuticals Cashflow Statement
0.000.00%
- $141.53m
- $90.73m
- $0.22m
Annual cashflow statement for Inovio Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -167 | -304 | -280 | -135 | -107 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 57 | 34 | 39.6 | 18.3 | 4.09 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -71.1 | 50.4 | 19.8 | -10.3 | -2.66 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -178 | -216 | -216 | -124 | -104 |
| Capital Expenditures | -1.52 | -1.23 | -0.969 | -0.321 | -0.488 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -57.3 | -174 | 111 | 87.7 | 105 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -58.8 | -175 | 110 | 87.4 | 104 |
| Financing Cash Flow Items | 2.38 | 0 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 465 | 211 | 81.8 | 5 | 51.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 229 | -180 | -24.8 | -32 | 51.5 |